The OPTIMIZE randomized trial comparing a novel, low-profile drug-eluting stent (DES) facilitating transradial access and direct stenting to existing DES did not establish noninferiority of the new stent...
source: Cath Lab Digest
As much as intracoronary physiologic measures can help operators identify potential ischemia-producing targets for percutaneous coronary intervention (PCI), they may also verify whether the procedure — even when angiographic...
source: Medscape
The FlowTriever percutaneous mechanical thrombectomy system (Inari Medical) is safe and provides immediate benefits to patients with acute pulmonary embolism, interim results of the real-world FLASH registry suggest. Among the first 230 patients enrolled in the study, there...
source: TCTMD
A large subgroup analysis of a randomized clinical trial showed neither a mortality risk nor benefit associated with the use of paclitaxel drug-coated devices (DCD) in the treatment of peripheral artery disease. The...
source: DAIC
Compare lung parenchymal and pulmonary artery (PA) growth and hemodynamics following early and delayed PA stent interventions for treatment of unilateral branch PA stenosis in swine. How the pulmonary...
source: Catheterization and Cardiovascular Interventions
Congenital left main coronary artery to right atrium fistulas with progression to aneurysm development are rare. Most patients remain asymptomatic, but for those with progressive symptoms, intervention is required.
source: Catheterization and Cardiovascular Interventions
Initial outcomes from the North American COVID-19 STEMI Registry provide a snapshot of the characteristics, presentation, treatment strategies and clinical outcomes of patients with STEMI and confirmed COVID-19. There has been “considerable...
source: Healio
People on oral anticoagulation undergoing percutaneous coronary intervention did not fare well with a treatment tailored to their high bleeding risk — Cobra PzF stent implantation and a short duration of dual antiplatelet therapy (DAPT) — the COBRA-REDUCE trial...
source: MedPage Today
Recently, there has been renewed interest in the treatment of higher-risk patients undergoing PCI for complex CAD. Novel techniques and equipment have expanded operators’ ability to treat patients with increasingly complicated lesion types. To address the growing problem...
source: Healio
Much like in the overall REDUCE-IT trial, icosapent ethyl reduced a broad range of adverse clinical outcomes in the large subgroup of patients who had undergone a prior PCI, a prespecified analysis shows.
In that group, which encompassed...
source: TCTMD
The ACC Imaging Council leads an in-depth discussion of the role of multimodality look in diagnosing and managing COVID-19 patients. This webinar will feature case studies and a panel discussion, and will be moderated by the...
source: American College of Cardiology
The HERO Registry welcomes support from hospitals and health systems, professional societies, key opinion leaders, and others to help us unite healthcare workers in our research community. Here are tools to help you spread the word...
source: Healthcare Worker Exposure Response & Outcomes
If you're in the throes of a heart attack, the choice is simple — or should be: Call 911 to get emergency care right away. That hasn't changed amid the coronavirus pandemic, even as staying home — and 6 feet away from people outside your household — is...
source: U.S. News & World Report
The COVID-19 pandemic has changed patient care in countless ways, but percutaneous coronary intervention (PCI) remains the recommended standard of care for ST-segment elevation myocardial infarction (STEMI) patients. Fibrinolysis...
source: Cardiovascular Business
Solid data is lacking, but an emerging body of evidence suggests that COVID-19 may predispose patients to arterial and venous thrombotic disease, and that some of the therapies under investigation may pose distinct drug-drug interactions...
source: TCTMD
